PB 59 of 2025

National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment (June Update) Instrument 2025

National Health Act 1953

I, REBECCA RICHARDSON, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, Disability and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under subsection 100(2) of the National Health Act 1953.

Dated 29 May 2025

REBECCA RICHARDSON

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Contents

1 Name

2 Commencement

3 Authority

4 Schedules

Schedule 1—Amendments

National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024
(PB 31 of 2024) 2

1.                Name

1.            This instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment (June Update) Instrument 2025.
2.            This instrument may also be cited as PB 59 of 2025.

1.                Commencement

1.            Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

1.             Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

1.                Authority

This instrument is made under subsection 100(2) of the National Health Act 1953.

1.                Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Efficient Funding of Chemotherapy) Special Arrangement 2024 (PB 31 of 2024)

1.                      Schedule 1, Part 1, entry for Nivolumab in each of the forms: Injection concentrate for I.V. infusion 40 mg in 4 mL; and Injection concentrate for I.V. infusion 100 mg in 10 mL

1.            omit from the column headed “Circumstances”: C14676
2.            insert in numerical order in the column headed “Circumstances”: C16657

1.                      Schedule 1, Part 2, entry for Nivolumab [Maximum Amount: 480 mg; Number of Repeats: 13]

omit from the column headed “Purposes”: P14676 substitute: P16657

1.                      Schedule 2, entry for Ondansetron in the form Tablet 4 mg (as hydrochloride dihydrate)

omit:

1.                      Schedule 2, entry for Ondansetron in the form Tablet (orally disintegrating) 8 mg

omit:

1.                      Schedule 2, entry for Ondansetron in the form Tablet 8 mg (as hydrochloride dihydrate)

omit:

1.                      Schedule 3, Part 1, omit entry for Circumstances Code “C14676”
2.                      Schedule 3, Part 1, after entry for Circumstances Code “C16472”

insert: